Bildkälla: Stockfoto

Xspray Pharma Q1’22: Truly Exciting Times Ahead - Redeye

Redeye leaves its view on Xspray following today’s Q1 report. We maintain our optimistic view of the case and reiterate our fair value range accordingly.

Redeye leaves its view on Xspray following today’s Q1 report. We maintain our optimistic view of the case and reiterate our fair value range accordingly.
Börsvärldens nyhetsbrev
ANNONSER